This technology was developed and patented by the manufacturers of Bovilis® Bovipast® RSP to allow the vaccine protect against multiple strains of Mannheimia (Pasteurella) haemolytica. Bovilis Bovipast RSP is the only cattle vaccine licensed to protect against Mannheimia (Pasteurella) haemolytica serotypes A1 and A6. Protection against both strains is vitally important and is unique to Bovilis Bovipast RSP. Do not underestimate the importance of A6 as it has been found in 63% of Mannheimia (Pasteurella) haemolytica infections in young beef animals!1

So how does IRP technology work?

  • Iron is needed for Mannheimia (Pasteurella) haemolytica to multiply
  • When Mannheimia (Pasteurella) haemolytica reach the lungs of the animal, Iron Regulated Proteins (IRPs) on their surface absorb iron
  • If cattle are vaccinated with Bovipast RSP before Mannheimia (Pasteurella) haemolytica reach the lungs, antibodies are produced against IRPs
  • These antibodies attach to the IRPs on the surface of Mannheimia (Pasteurella) haemolytica
  • These antibodies reduce the ability of the bacteria to absorb iron
  • This results in the failure of the Mannheimia (Pasteurella) haemolytica to multiply, thereby reducing clinical signs of pneumonia (fever, depression etc.)

    • Please see the video below which explains more about IRP technology

    Bovipast RSP - IRP Technology from MSD Animal Health.

    Outbreaks of Bovine Respiratory Disease (BRD) continue to be a cause of significant economic loss and hardship for all Irish beef production systems. The fact is, many contributing agents can produce similar clinical signs and this makes it difficult to identify which pathogen is causing the respiratory disease. Good animal husbandry and farm management practices, including a comprehensive herd vaccination scheme, remain the best strategy to defend against a BRD outbreak this autumn.

    Use Bovipast RSP in your weanlings this autumn!

  • Only Bovipast RSP contains IRP technology
  • Bovipast RSP provides the broadest protection against Pasteurella* and viral pneumonia**
  • Only Bovipast RSP is licensed to protect against both Mannheimia (Pasteurella) haemolytica serotypes A1 and A6

    • Use medicines responsibly

    Bovilis Bovipast® RSP contains inactivated BRS strain EV908, PI-3 strain SF-4 Reisinger and Mannheimia haemolytica A1 strain M4/1

    Withdrawal periods: zero days. Legal categories: ROI POM(E) NI POM-V

    For further information see SPC, contact prescriber or MSD Animal Health, Red Oak North, South County Business Park, Leopardstown, Dublin 18, Ireland. Tel: +353(0)1 2970220. E-Mail: vet-support.ie@merck.com Web: www.msd-animal-health.ie

    1. Timsit, E et al. Transmission dynamics of Mannheimia haemolytica in newly-received beef bulls at fattening operations. Veterinary Microbiology 161 (2013) 295–304.

    * Mannheimia haemolytica serotypes A1 and/or A6 ** BRS-Virus and/or PI-3-Virus

    IE/BBR/0816/0009 August 2016